Steward Partners Investment Advisory, LLC Avadel Pharmaceuticals PLC Transaction History

Steward Partners Investment Advisory, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 04, 2022	BUY	$1.07 - $6.95 $1,605 - $10,425	1,500 Added 187.5%	2,300 $6,000
Q1 2022 May 02, 2022	BUY	$5.46 - $8.29 $2,730 - $4,145	500 Added 166.67%	800 $5,000
Q2 2021 Aug 13, 2021	SELL	$6.73 - $9.05 $96,252 - $129,433	-14,302 Reduced 97.95%	300 $2,000
Q1 2021 May 14, 2021	BUY	$6.61 - $10.07 $53,223 - $81,083	8,052 Added 122.93%	14,602 $132,000
Q4 2020 Feb 11, 2021	SELL	$5.03 - $7.95 $10,060 - $15,900	-2,000 Reduced 23.39%	6,550 $44,000
Q3 2020 Oct 30, 2020	BUY	$5.02 - $8.98 $9,939 - $17,780	1,980 Added 30.14%	8,550 $43,000
Q2 2020 Aug 06, 2020	BUY	$7.25 - $11.75 $3,770 - $6,110	520 Added 8.6%	6,570 $53,000
Q1 2020 Apr 29, 2020	BUY	$4.06 - $10.64 $7,104 - $18,620	1,750 Added 40.7%	6,050 $48,000
Q4 2019 Jan 17, 2020	BUY	$3.34 - $7.7 $13,360 - $30,800	4,000 Added 1333.33%	4,300 $32,000
Q2 2019 Jul 25, 2019	BUY	$1.09 - $3.19 $327 - $957	300 New	300 $0
Q4 2018 Jan 15, 2019	SELL	$1.74 - $4.66 $522 - $1,398	-300 Closed	0 $0
Q4 2017 Jan 19, 2018	BUY	$8.03 - $11.25 $2,409 - $3,375	300	300 $2,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Steward Partners Investment Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Steward Partners Investment Advisory, LLC with notifications on news.